Synthetic biology for the chemogenetic manipulation of pain pathways

用于疼痛通路化学遗传学操纵的合成生物学

基本信息

批准号：
9895148
负责人：
Andrew D Ellington
金额：
$ 19.25万
依托单位：
UNIVERSITY OF TEXAS AT AUSTIN
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-09-15 至 2021-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9895148
关键词：
Absence of pain sensation Affinity Analgesics Animal Model Biological Assay Biological Sciences Biology Brain CNR2 gene Cannabidiol Cannabinoids Cells Chronic Clinic Collaborations Complex Coupled Couples Cultured Cells Development Directed Molecular Evolution Discipline Dose Electrophysiology (science)Emulsions Engineering Enzymes Flying body movement Future G-Protein-Coupled Receptors Genes Individual Ion Channel Lead Learning Libraries Ligands Memory Methods Minor Modeling Movement Mus Neural Pathways Neurobiology Neurons Neurophysiology - biologic function Oils Pain Pain management Pathway interactions Patients Performance Pheromone Polymerase Prevention Production Proteins Radar Receptor Signaling Scheme Sensory Receptors Signal Pathway Signal Transduction Testing Variant Water Work Yeasts addiction cannabinoid drug combat designer receptors exclusively activated by designer drugs dopaminergic neuron gene therapy genetic regulatory protein mouse model nano nanomolar novel pain model pain relief receptor relating to nervous system selective expression side effect synthetic biology theories tool

项目摘要

Project Summary The methods of synthetic biology have transformed practice throughout the biological sciences, but have yet to find wide application in neurobiology. This is in part because many signaling receptors and pathways in the brains are shared, limiting the latitude for narrowly targeted engineering strategies. To create a wider range of tools for selective cell modulation, we propose to develop directed evolution methods that will generate orthogonal neural receptors that respond to cannabinoids and offer multiple different chemogenetic control points across the brain and thereby open the way to a synthetic neurobiology. The proposed methods should yield very High Affinity receptors, that have Validated Orthogonalities for their receptor:ligand Couples. Our HAVOCs will stand in contrast to current DREADD and DART approaches in that they will allow the use of natural effectors, but at much lower concentrations, in essence flying below the ‘radar cover’ of endogenous receptors in the brain. In particular, we will use HAVOCs to examine the gate theory of pain, and in consequence serve as a surrogate model for targeted nano-dosing strategies for cannabinoids to safely promote analgesia and combat addiction. As a starting point for the development of nano-dosing strategies, we will focus on the CB2 receptor, which is sparsely expressed in the brain, but which has known functions in inhibiting dopaminergic neurons. Using our novel directed evolution method, Compartmentalized Partnered Replication (CPR), we will initially evolve individual variants of CB2 that can interact with high affinity with the cannabinoids b-caryophyllene, cannabidiol (CBD), and other minor cannabinoids (Aim 1). We will proof the utility of these compounds and their evolved receptors with isolated neurons and directly in a mouse model for pain (Aim 2). While movement to the clinic will ultimately require introduction of novel receptors into patients, likely via gene therapies, the ability to target protein production in particular neural pathways may provide one of the few viable methods for the chronic treatment of pain. Into the future, the directed evolution strategies we have developed are fungible between multiple different receptors and receptor types, and we suggest that HAVOCs may therefore serve as generalizable neurotechnological tools to understand and manipulate a variety of neural functions.

项目概要合成生物学的方法已经改变了整个生物科学的实践，但尚未在神经生物学中得到广泛应用，部分原因是许多信号受体和通路。大脑是共享的，限制了目标狭窄的工程策略的自由度，从而创造了更广泛的范围。作为选择性细胞调节的工具，我们建议开发定向进化方法，该方法将产生对大麻素做出反应并提供多种不同化学遗传学控制点的正交神经受体跨大脑，从而为合成神经生物学开辟道路。所提出的方法应该会产生非常好的效果。高亲和力受体，已验证其受体的正交性：我们的 HAVOC 将。与当前的 DREADD 和 DART 方法形成对比，因为它们允许使用自然效应器，但浓度要低得多，本质上是在大脑内源性受体的“雷达罩”下方飞行。特别是，我们将使用 HAVOC 来检查疼痛的门理论，并因此作为替代品大麻素靶向纳米剂量策略的模型，以安全地促进镇痛和对抗成瘾。作为开发纳米剂量策略的起点，我们将重点关注 CB2 受体，它是在大脑中稀疏表达，但已知其具有抑制多巴胺能神经元的功能。新颖的定向进化方法，分区合作复制（CPR），我们将首先进化 CB2 的各个变体可以与大麻素 b-石竹烯、大麻二酚以高亲和力相互作用（CBD）和其他次要大麻素（目标 1）我们将证明这些化合物的实用性及其进化。受体与分离的神经元并直接在小鼠模型中进行疼痛（目标 2）。最终需要将新的受体引入患者体内，可能通过基因疗法，靶向的能力特别是神经通路中的蛋白质生产可能为慢性病提供少数可行的方法之一未来，我们开发的定向进化策略是可以互换的。多种不同的受体和受体类型，因此我们建议 HAVOC 可以作为用于理解和操纵各种神经功能的通用神经技术工具。